Related Experiment Video
Updated: Jun 17, 2026
09:44
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Investigational agents for salvage
1HIV Services, St Stephen's Centre, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK. anton.pozniak@chelwest.nhs.uk
Current Opinion in HIV and AIDS
|January 6, 2010
Summary
New antiretroviral therapies show promise for patients with highly resistant HIV-1. Ongoing research aims to develop effective treatments for individuals experiencing virological failure despite extensive drug experience.
Area of Science:
- Infectious Diseases
- Virology
- Pharmacology
Background:
- Managing highly drug-experienced patients with Human Immunodeficiency Virus type 1 (HIV-1) presents significant challenges.
- Recent advancements have introduced novel compounds active against drug-resistant HIV-1 strains.
Purpose of the Study:
- To review current knowledge on investigational agents for patients with highly resistant HIV-1.
- To examine potential future therapeutic options for highly experienced individuals.
Main Methods:
- Review of early-phase therapy studies.
- Analysis of dose-ranging efficacy and safety clinical trials for investigational drugs.
Main Results:
- Several investigational drugs are progressing towards licensing.
- Development of new drugs is challenging due to requirements for lower toxicity and activity against resistant viruses.
Conclusions:
- The majority of highly experienced patients with virological failure can achieve undetectable HIV-1 viral loads.
- New drugs are essential for patients who continue to experience virological failure and develop further resistance.
